AMLX (AMLX) Stock Analysis
Verdict: HOLD
Post-withdrawal pivot relies on a $226M cash cushion to bridge clinical binary events; price momentum signals speculative accumulation.
Investment score: 64/100
Amylyx is in a transition phase. While the balance sheet is strong enough to fund operations through 2026, the lack of current revenue and heavy insider selling suggest caution at 52-week highs.
Peers
| Peer | P/E | P/B | P/S | EV/EBITDA | ROIC % | Net margin % |
|---|---|---|---|---|---|---|
| PBH | 13.07 | 1.29 | 2.24 | 10.33 | — | 0.17 |
| NKTR | -8.33 | 3.01 | 24.63 | -10.97 | — | -2.84 |
| NUVB | -15.48 | 7.14 | 15.95 | -16.69 | — | -1.02 |
| VRNO.NE | -1.41 | 0.54 | 0.47 | 4.14 | — | -0.33 |
| HRMY | 14.10 | 2.26 | 2.29 | 7.17 | — | 0.16 |